Pfizer's cancer drug combo improves overall survival in late-stage study

Pfizer's combination of Talzenna and Xtandi has shown a notable improvement in overall survival rates for patients with metastatic castration-resistant prostate cancer (mCRPC) in a late-stage study. This combination works regardless of genetic mutations, offering a significant advancement over using Xtandi alone. Pfizer aims to update Talzenna's label globally based on these promising results.

from Science News - Times of India https://ift.tt/xI9FMTA